These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 33993819)

  • 1. Heterozygous familial hypercholesterolemia: prevalence and control rates.
    Polychronopoulos G; Tzavelas M; Tziomalos K
    Expert Rev Endocrinol Metab; 2021 Jul; 16(4):175-179. PubMed ID: 33993819
    [No Abstract]   [Full Text] [Related]  

  • 2. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
    Arca M
    Atherosclerosis; 2017 Jan; 256():134-145. PubMed ID: 27993383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Heterozygous familial hypercholesterolemia: the first challenge for anti-PCSK9 monoclonal antibodies].
    Zambon A
    G Ital Cardiol (Rome); 2016 Apr; 17(4 Suppl 1):22S-30. PubMed ID: 27312020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy.
    Hartgers ML; Besseling J; Stroes ES; Wittekoek J; Rutten JHW; de Graaf J; Visseren FLJ; Imholz BPM; Roeters van Lennep JE; Huijgen R; Kastelein JJP; Hovingh GK
    J Clin Lipidol; 2018; 12(4):972-980.e1. PubMed ID: 29934068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Effectiveness of PCSK9 Inhibitors in Reducing LDL-C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries.
    Arca M; Celant S; Olimpieri PP; Colatrella A; Tomassini L; D'Erasmo L; Averna M; Zambon A; Catapano AL; Russo P
    J Am Heart Assoc; 2023 Nov; 12(21):e026550. PubMed ID: 37850449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
    Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
    J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proprotein convertase subtilisin/kexin 9 inhibition in patients with familial hypercholesterolemia: Initial clinical experience.
    Galema-Boers AMH; Lenzen MJ; Sijbrands EJ; Roeters van Lennep JE
    J Clin Lipidol; 2017; 11(3):674-681. PubMed ID: 28506389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of heterozygous familial hypercholesterolemia: what does the future hold?
    Polychronopoulos G; Tziomalos K
    Expert Rev Clin Pharmacol; 2020 Nov; 13(11):1229-1234. PubMed ID: 33070644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia.
    Tomlinson B; Patil NG; Fok M; Lam CWK
    Endocrinol Metab (Seoul); 2021 Apr; 36(2):279-295. PubMed ID: 33866776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry.
    Vrablik M; Raslová K; Vohnout B; Blaha V; Satny M; Kyselak O; Vaclova M; Urbanek R; Maskova J; Soska V; Freiberger T
    Atherosclerosis; 2018 Oct; 277():355-361. PubMed ID: 30270071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy.
    Toscano A; Cinquegrani M; Scuruchi M; Di Pino A; Piro S; Ferrara V; Morace C; Lo Gullo A; Imbalzano E; Purrello F; Squadrito G; Scicali R; Mandraffino G
    Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement].
    Cybulska B; Gaciong Z; Hoffman P; Jankowski P; Kłosiewicz-Latoszek L; Kaźmierczak J; Mitręga K; Opolski G; Pająk A; Ponikowski P; Rynkiewicz A; Stępińska J; Średniawa B; Kalarus Z
    Kardiol Pol; 2016; 74(4):394-8. PubMed ID: 27098076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C.
    van Delden XM; Huijgen R; Wolmarans KH; Brice BC; Barron JK; Blom DJ; Marais AD
    Atherosclerosis; 2018 Oct; 277():327-333. PubMed ID: 30270067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arterial stiffness improvement after adding on PCSK9 inhibitors or ezetimibe to high-intensity statins in patients with familial hypercholesterolemia: A Two-Lipid Center Real-World Experience.
    Mandraffino G; Scicali R; Rodríguez-Carrio J; Savarino F; Mamone F; Scuruchi M; Cinquegrani M; Imbalzano E; Di Pino A; Piro S; Rabuazzo AM; Squadrito G; Purrello F; Saitta A
    J Clin Lipidol; 2020; 14(2):231-240. PubMed ID: 32111581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia.
    Kastelein JJ; Hovingh GK; Langslet G; Baccara-Dinet MT; Gipe DA; Chaudhari U; Zhao J; Minini P; Farnier M
    J Clin Lipidol; 2017; 11(1):195-203.e4. PubMed ID: 28391886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and emerging monoclonal antibodies for treating familial hypercholesterolemia in children.
    Reijman MD; Kusters DM; Wiegman A
    Expert Opin Biol Ther; 2024 Apr; 24(4):243-249. PubMed ID: 38501269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.
    Glueck CJ; Shah P; Goldenberg N; Prince M; Lee K; Jetty V; Kumar A; Goldenberg M; Wang P
    Lipids Health Dis; 2016 Mar; 15():55. PubMed ID: 26968977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The detection of heterozygous familial hypercholesterolemia in Ireland.
    O'Kane MJ; Menown IB; Graham I; Maher V; Tomkin G; Nicholls P; Graham C
    Adv Ther; 2012 May; 29(5):456-63. PubMed ID: 22610724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.